Why Biologics Companies Are Increasingly Turning to CDMOs

Why Biologics Companies Are Increasingly Turning to CDMOs

The development and manufacturing of biologic medicines has become increasingly complex. From monoclonal antibodies and recombinant proteins to biosimilars, cell and gene therapies, antibody-drug conjugates, and mRNA-based products, biopharmaceutical companies require highly specialized capabilities to move products from development to commercial production.

This complexity is creating a strong opportunity for Biologics Contract Development and Manufacturing Organizations (CDMOs). Pharmaceutical and biotechnology companies are increasingly outsourcing development and manufacturing activities to specialized partners that can provide advanced facilities, technical expertise, analytical capabilities, and regulatory support.

According to the market analysis, the global Biologics CDMO Market was valued at USD 45.6 billion in 2025 and is projected to reach USD 95.5 billion by 2035, representing a 7.46% CAGR from 2026 to 2035.

Why Are Biopharmaceutical Companies Outsourcing Manufacturing?

Building an internal biologics manufacturing operation requires significant investment in facilities, bioreactors, purification systems, cleanrooms, analytical laboratories, quality systems, and specialized personnel.

At the same time, biologic manufacturing involves complex processes and stringent quality requirements. As the biologics pipeline expands, outsourcing provides pharmaceutical and biotechnology companies with access to established manufacturing infrastructure without having to develop every capability internally.

The shift toward asset-light operating models is therefore becoming an important factor behind CDMO demand.

Monoclonal Antibodies Continue to Anchor the Market

Among different molecule types, Monoclonal Antibodies (mAbs) accounted for approximately 43.00% of the market in 2025, making them the leading segment.

The strong position of mAbs reflects their importance across the biologics pipeline and the need for specialized manufacturing capabilities. CDMOs supporting mAb programs can provide services spanning process development, drug substance manufacturing, drug product production, analytical development, and commercial-scale manufacturing.

Other important molecule categories include recombinant proteins, vaccines and viral vectors, biosimilars, cell and gene therapies, mRNA-based biologics, and antibody-drug conjugates.

Drug Substance Manufacturing Holds a Major Position

By service type, Drug Substance Manufacturing accounted for 43.00% of the market in 2025.

Drug substance manufacturing represents a critical stage in biologics production and requires sophisticated upstream and downstream processing capabilities. CDMOs with scalable bioprocessing infrastructure can support clients as programs progress from clinical development toward commercial production.

The broader service landscape also includes drug product and fill-finish manufacturing, process and analytical development, clinical manufacturing, and regulatory support.

Commercial-Scale Manufacturing Is Gaining Importance

The expansion of biologic pipelines is increasing the need for manufacturing capacity beyond early-stage clinical development.

Commercial-scale manufacturing represented approximately 48.00% of the market in 2025, highlighting the importance of CDMOs capable of supporting large-volume production and the transition from development to commercialization.

This creates opportunities for CDMOs that can provide integrated services and maintain consistent quality while scaling production.

Biosimilars Open a New Avenue for CDMOs

The expansion of biosimilars is another major factor supporting the biologics outsourcing market.

As patents expire on established biologic medicines, pharmaceutical companies are pursuing biosimilar development programs. These products require reliable and cost-efficient manufacturing capabilities, creating additional demand for specialized CDMO partnerships.

The source also identifies growing biosimilar manufacturing and increasing outsourcing by large pharmaceutical companies as important opportunities for the industry.

Cell and Gene Therapy Are Changing CDMO Requirements

The emergence of advanced therapies is changing what pharmaceutical companies expect from CDMO partners.

Cell and gene therapies often require specialized manufacturing processes, viral-vector capabilities, controlled environments, and sophisticated analytical testing. Similarly, mRNA-based therapeutics require specialized production platforms and expertise.

The market analysis identifies cell and gene therapies, mRNA biologics, and next-generation biologics as important areas of future CDMO opportunity.

Single-Use Technologies Improve Manufacturing Flexibility

Technology is becoming an important differentiator among biologics CDMOs.

The increasing adoption of single-use bioprocessing, continuous manufacturing, and process analytical technology (PAT) can improve manufacturing flexibility and support faster scale-up.

These technologies can also reduce some infrastructure requirements and allow CDMOs to respond more efficiently to changing production needs.

Biotechnology Companies Are Major CDMO Customers

By end user, Biotechnology Companies accounted for approximately 42.00% of the market in 2025.

Early-stage biotechnology companies often have promising drug candidates but may not possess the manufacturing infrastructure required for clinical or commercial production. Partnering with a CDMO can provide access to specialized capabilities while allowing biotech companies to concentrate their resources on discovery, clinical development, and commercialization.

North America Remains the Largest Regional Market

North America accounted for approximately 42.12% of the global Biologics CDMO Market in 2025, making it the largest regional market.

The region benefits from a strong concentration of biopharmaceutical and biotechnology companies, established GMP manufacturing infrastructure, significant R&D investment, and a well-developed regulatory environment.

The North American market was valued at approximately USD 19.2 billion in 2025 and is projected to reach USD 35.81 billion by 2035.

The United States Drives North American Demand

The United States represented approximately 89.00% of the North American Biologics CDMO Market in 2025, with a market value of nearly USD 17 billion.

The country's large concentration of biopharmaceutical innovators and clinical-stage biotechnology companies continues to support demand for outsourced biologics manufacturing.

Asia Pacific Emerges as a High-Growth Region

While North America currently leads the market, Asia Pacific is projected to be the fastest-growing region, with an expected 10.30% CAGR from 2026 to 2035.

The region's growing importance is supported by expanding biopharmaceutical manufacturing capabilities, cost-competitive production environments, increasing healthcare investment, and the development of domestic biotechnology industries.

By 2032, Asia Pacific's share is projected to reach approximately 30.50%, compared with 23.96% in 2025.

India and China Create New Manufacturing Opportunities

Emerging Asian markets are becoming increasingly important for biologics manufacturing.

The source projects the India Biologics CDMO Market to grow from USD 1.4 billion in 2025 to USD 4.9 billion by 2035, representing a 12.87% CAGR.

China is also positioned as a significant regional market, with its Biologics CDMO Market projected to increase from USD 3.4 billion in 2025 to USD 9.9 billion by 2035, at a 10.97% CAGR.

These markets offer opportunities for capacity expansion, biosimilar manufacturing, cell therapy production, and partnerships with international biopharmaceutical companies.

High Investment Requirements Remain a Challenge

Despite strong demand, operating a biologics CDMO is capital intensive.

Manufacturing facilities require sophisticated bioreactors, downstream purification systems, cleanroom environments, quality-control laboratories, and GMP-compliant infrastructure. CDMOs must also continuously invest in workforce development, technology upgrades, validation, and regulatory compliance.

Technology transfer can also be challenging when manufacturing processes move from a pharmaceutical or biotechnology company to an external CDMO.

What Is Next for the Biologics CDMO Market?

The future of biologics outsourcing is likely to be shaped by several interconnected developments:

• Growing biologics and biosimilar pipelines

• Increasing pharmaceutical outsourcing

• Expansion of cell and gene therapy manufacturing

• Rising demand for mRNA and ADC production

• Greater adoption of single-use technologies

• Increasing commercial-scale manufacturing requirements

• Expansion of CDMO capacity in Asia Pacific

• Greater demand for integrated development-to-commercial manufacturing services

The market analysis also presents three potential growth scenarios. Under the likely scenario, the market reaches approximately USD 95.57 billion by 2035, while the optimistic scenario reaches approximately USD 107.95 billion.

Conclusion

The biologics industry is moving toward increasingly specialized and flexible manufacturing models. As drug pipelines become more complex and pharmaceutical companies seek to control capital expenditure, CDMOs are becoming strategic partners rather than simply outsourced production providers.

Monoclonal antibodies and drug substance manufacturing currently represent major portions of the market, while biosimilars, cell and gene therapies, mRNA, ADCs, and advanced manufacturing technologies are creating new growth opportunities.

With the global Biologics CDMO Market expected to reach USD 95.5 billion by 2035, the industry is positioned for substantial expansion as biopharmaceutical companies increasingly rely on external expertise and manufacturing capacity.

Explore the Full Biologics CDMO Market Analysis

For detailed market sizing, segmentation, regional forecasts, competitive analysis, market dynamics, and strategic insights, explore the Biologics CDMO Market report by BrandEssence Research.